Danish pharmaceuticals giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced on Monday a name change to just Novo, hoping it will be more “memorable and relevant” for clients.
The rebrand comes ahead of a strategic presentation on September 21, when executives are to lay out their plan for “a faster, more competitive and increasingly consumer-driven market”.
The company is battling fierce competition in the anti-obesity sector, where its hugely successful Ozempic and Wegovy treatments have spurred rivals to catch up.
It released a new tablet form of Wegovy in the United States in January, and the pill was recently approved for use in Europe.